Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04702282 |
| Other study ID # |
H-16027950 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 1, 2017 |
| Est. completion date |
September 30, 2019 |
Study information
| Verified date |
January 2021 |
| Source |
Hvidovre University Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The aim of this study was to investigate the pharmacokinetics of free and total ropivacaine
after unilateral and bilateral TKA. A population model was successfully built and peak free
ropivacaine concentration stayed below previously proposed toxic thresholds in patients
undergoing unilateral as well as bilateral TKA receiving LIA with high dose ropivacaine.
Description:
Thirteen unilateral TKA and fifteen bilateral TKA patients were included in the study. All
patients were operated in a well-described fast-track setup without use of drains or
tourniquet.21 A standard midline skin incision with a medial para-patellar capsulotomy was
used. All patients were operated with cemented CR components. In bilateral TKA cases, both
knees were operated in one setting with the left knee always being operated first, and the
second knee being operated sequentially in the same setting immediately following closure of
the first knee. Patients undergoing unilateral TKA received spinal anesthesia with 2 mL 0.5%
hyperbaric bupivacaine, whereas patients scheduled for bilateral TKA received spinal
anaesthesia with 3 mL 0.5% hyperbaric bupivacaine. Local infiltration anesthesia was
performed as previously described with 200 mL 0.2% ropivacaine (400 mg) mixed with 1 mL 1
mg/mL epinephrine injected periarticularly in each knee. The first 50 mL were injected into
the posterior capsule, 100 mL were injected into medial, anterior and lateral structures of
the knee and capsule and the final 50 mL were injected in the subcutaneous tissue. All
patients were mobilized on the day of surgery and thromboembolic prophylaxis started 6-8
hours postoperatively with rivaroxaban tablets (10 mg) given once daily until discharge. No
extended thromboembolic prophylaxis was given to any patient. All patient received 1 g
intravenous tranexamic acid preoperatively and 1 g 3 hours postoperatively.
Preoperative blood samples were taken within a week of surgery including electrolytes,
hemoglobin and serum creatinine levels. Baseline blood sample was taken just before incision
of the first knee, and additional blood samples were drawn at 1, 5, 30 and 60 minutes as well
as 2, 4, 8 and 24 hours after incision following unilateral TKA and at 1, 5, 30 minutes after
the incision of the first knee and 0, 5 and 15 minutes after incision of the second knee as
well as after 1,2, 4 8 and 24 hours (total 9 and 12 timepoints within 24 hours for unilateral
and bilateral TKA, respectively). Patient demographics were recorded and included age,
gender, height and weight.
Ropivacaine measurement Ropivacaine concentrations were determined in plasma samples using
liquid-chromatography coupled to mass spectrometry following a fully validated method
